CCR3 inhibition for ocular angiogenesis and macular degeneration
US8008092B2 · kind B2 · utility
15Cited by
2References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 8, 2008 |
| Grant date | Aug 30, 2011 |
| Priority date | — |
| Expiry date | Oct 8, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/164
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.